WASHINGTON — On Thursday, the Food and Drug Administration plans to start publishing the names of pharmaceutical companies that have been accused of withholding samples of drugs from generic manufacturers, Commissioner Scott Gottlieb told STAT.

This is part of the Trump administration’s broader plan to bring down drug prices by fostering competition. In a speech Monday, Secretary of Health and Human Services Alex Azar highlighted this forthcoming action by the FDA as one way to “call out the manufacturers who may be abusing the rules that built our free market for drugs.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy